Leukemia drug TGRX-678 gets a body scan: tiny study tracks its journey

NCT ID NCT06986772

Completed Knowledge-focused Sponsor: Shenzhen TargetRx Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 1 study gave 6 healthy Chinese men a single dose of the leukemia drug TGRX-678 to see how the body absorbs, breaks down, and gets rid of it. Researchers measured radioactivity in blood, urine, and stool to map the drug's path. No treatment was given—just understanding how the drug behaves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TGRX-678 (a tyrosine kinase inhibitor for chronic myeloid leukemia)
What this could lead to: If successful, this study will help doctors understand how TGRX-678 moves through the body and how it is eliminated, which can guide future dosing and safety decisions.
What could go wrong: This is a very early, small study in just 6 healthy men, not patients. It is designed to measure drug processing, not to test effectiveness or safety for treating leukemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.